Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI

European Journal of Medical Research

Volumn 11, Issue 2, 2006, Pages 58-65

  Seemann, Marcus D ^a   Meisetschlaeger, G ^a   Gaa, J ^a   Rummeny, E J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Carcinoid tumors; Computed tomography (CT); Magnetic resonance imaging (MRI); PET CT; PET MRI; Positron emission tomography (PET); Whole body imaging

Indexed keywords

DIATRIZOATE; IMERON; NONIONIC CONTRAST MEDIUM; OCTREOTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CARCINOID; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY SCANNER;

AGED; CARCINOID TUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 33644747712     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290: 3199-3206
2. Bader TR, Semelka RC, Chiu VC, Armao DM, Woosley JT (2001) MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging 14: 261-269
3. Blomqvist L, Torkzad MR (2003) Whole-body imaging with MRI or PET/CT: the future for single-modality imaging in oncology? JAMA 290: 3248-3249
4. Bollen EC, Goei R, van't Hof-Grootenboer BE, Versteege CW, Engelshove HA, Lamers RJ (1994) Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer. Ann Thorac Surg 58: 158-162
5. Capella C, Heitz PU, Hoefler H, Solcia E, Kloeppel G (1994) Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55: 11-23
6. Dromain C, de Baere T, Baudin E, Galline J, Ducreux M, Boige V, Duvillard P, Laplanche A, Caillet H, Lasser P, Schlumberger M, Sigal R (2003) MR Imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR 180: 121-128
7. Fujita T, Yamaji Y, Sato M, Murao K, Takehara J (1994) Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 55: 1797-1806
8. Gaa J, Fischer H, Laub G, Georgi M (1996) Breath-hold MR imaging of focal liver lesions: comparison of fast and ultrafast techniques. Eur Radiol 6: 838-843
9. Gaa J, Rummeny EJ, Seemann MD (2004) Whole-body imaging with PET/MRI. Eur J Med Res 9: 309-312
10. Gibril F, Reynolds JC, Doppmann JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 125: 26-34
11. Hofland LJ, Lamberts SW (2001) Somatostatin receptor subtype expression in human tumors. Ann Oncol 12 (Suppl 2): 31-36
12. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB (2004) Recent advances in radiological und radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 151: 15-27
13. Kloeppel G, Heitz PU, Capella C, Solcia E (1996) Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 20: 132-141
14. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, Townsend DW (2000) Combined PET/CT imaging in oncology: impact on patient management. Clin Pos Imag 3: 223-230
15. 111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731
16. Kvols LK, Moertel CG, O'Connel MJ, Schutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663-666
17. Lamberts SWJ, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12: 430-482
18. Martin DR, Semelka RC (2001) Imaging of benign and malignant focal liver lesions. Magn Reson Imaging Clin N AM 9: 785-802
19. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198
20. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC (1998) Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 206: 143-150
21. Reubi JC, Kvols LK, Waser B, Nagomey DM, Heitz PU, Charboneau JW, Reading CC, Moertel C (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50: 569-577
22. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B, Gualdi G, Delle Fave G (1996) SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 37: 1452-1456
23. 111-pentetreotide. J Nucl Med 38: 886-887
24. Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G (2003) Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 44: 359-368
25. Seemann MD (2004) PET/CT: fundamental principles. Eur J Med Res 9: 241-246
26. Seemann MD (2005) Whole-body PET/MRI: the future in oncological imaging. Technol Cancer Res Treat 4: 577-582
27. Seemann MD, Gaa J (2005) Images in cardiovascular medicine. Cardiac metastasis: visualization with positron emission tomography, computed tomography, magnetic resonance imaging, positron emission tomography/computed tomography, and positron emission tomography/magnetic resonance imaging. Circulation 112: e329-330
28. Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19: 61-77
29. Stinner B, Kisker O, Zielke A, Rothmund M (1996) Surgical management for carcinoid tumors of small bowel, appendix, colon and rectum. World J Surg 20: 183-188
30. Sutliff VE, Doppman JL, Gibril F, Venzon DJ, Yu F, Serrano J, Jensen RT (1997) Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 15: 2420-2431
31. 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 30: 117-122